BACKGROUND: Tougu Xiaotong Capsule (TGXTC) is a clinical prescription for the treatment of osteoarthritis; however, its mechanism has not been fully elucidated. Urokinase-type plasminogen activator (uPA) system
participating in the degradation of the extracellular matrix of articular cartilage and hyperplasia of joint synovium plays an important role in the pathological process of osteoarthritis.
OBJECTIVE: To investigate the effects of TGXTC medicated serum on the expression of uPA, uPA receptor (uPAR), plasminogen activator inhibitors (PAIs), matrix metalloproteinase-3 (MMP-3), interleukin-1 beta (IL-1β) and tumor necrosis factor-α (TNF-α) in osteoarthritis synovial cells of rats and to discuss the mechanism by TGXTC medicated serum prevents and cures osteoarthritis.
METHODS: Rat models with knee osteoarthritis were established by injecting 4% papain into the knee joint cavity. Primary synoviocytes and osteoarthritis synoviocytes were cultured with collagenase digestion method. The cultured synoviocytes were divided into normal group, model group and TGXTC group. The western blot method was adopted to detect uPA, uPAR, PAI, MMP-3, IL-1β and TNF-α protein expression of synoviocytes after acting by TGXTC medicated serum for 72 hours.
ESULTS AND CONCLUSION: The expression of uPA, uPAR, MMP-3, IL-1β and TNF-α were decreased, while PAI was increased in the TGXTC group, and there were significant differences when compared with model group. In a word, TGXTC can significantly inhibit the expression of uPA, uPAR, MMP-3, IL-1β, TNF-α, and improve PAI expression in synoviocytes, which may partly explain the mechanism of the treatment of Tougu Xiaotong Capsule on osteoarthritis.
中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程